Document Detail

Higher urinary excretion of inorganic phosphate during early induction chemotherapy predicts a good prognosis in childhood acute leukemia.
MedLine Citation:
PMID:  21423043     Owner:  NLM     Status:  MEDLINE    
The rapidity of response to induction therapy is emerging as an important prognostic factor in children with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Urine inorganic phosphate (IP) and uric acid (UA) may increase in patients with acute leukemia who undergo their induction chemotherapy, owing to the breakdown of tumor cells. The crystallization of UA or calcium phosphate in renal tubules can result in acute tumor lysis syndrome (ATLS). Some reports indicate that patients who experience ATLS have a better prognosis than those who do not. We investigated the relationship between urinary IP and UA excretion and treatment outcome in children with acute leukemia. Participants included 93 patients with ALL and 31 patients with AML. Urine samples were collected and measured for the first 3 days of induction chemotherapy. Among patients with ALL, urinary IP excretion was significantly higher in patients without relapse than in those with relapse and correlated with long-term outcome. Among patients with AML, urinary IP excretion was significantly higher in patients without induction failure (IF) than those with IF. We propose that higher urinary IP excretion could be a useful prognostic marker for determining favorable outcomes in patients with acute leukemia.
Mizuho Ichikawa; Ryoji Kobayashi; Masahide Nakajima; Jun Inamoto; Daisuke Suzuki; Yuko Cho; Makoto Kaneda; Makoto Yoshida; Tadashi Ariga
Related Documents :
7069473 - Observer variability in grading patients with subarachnoid hemorrhage.
25402383 - Graves' disease after treatment with alemtuzumab for multiple sclerosis.
8777613 - A urodynamic evaluation of patients with renal, upper and lower ureteric stones.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of pediatric hematology/oncology     Volume:  33     ISSN:  1536-3678     ISO Abbreviation:  J. Pediatr. Hematol. Oncol.     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-04-25     Completed Date:  2011-06-30     Revised Date:  2011-10-06    
Medline Journal Info:
Nlm Unique ID:  9505928     Medline TA:  J Pediatr Hematol Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e143-8     Citation Subset:  IM    
Department of Pediatrics, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Biological Markers / urine
Child, Preschool
Leukemia, Myeloid, Acute / diagnosis,  drug therapy*,  urine
Phosphates / urine*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis,  drug therapy*,  urine
Predictive Value of Tests
Treatment Outcome
Tumor Lysis Syndrome / diagnosis,  urine*
Uric Acid / urine
Reg. No./Substance:
0/Biological Markers; 0/Phosphates; 69-93-2/Uric Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Recovery of ovarian function and pregnancy in a patient with AML after myeloablative busulphan-based...
Next Document:  Methylation Pattern of Calcitonin (CALCA) Gene in Pediatric Acute Leukemia.